Search clinical trials for: Quisinostat

Total 3 results

Janssen Research & Development, LLC

Completed

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Lymphoma, T-Cell, Cutaneous

France, United Kingdom, Spain, Portugal, United States, Germany
NewVac LLC
Janssen Pharmaceutica N.V., Belgium

Completed

Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

Ovarian Cancer

Russian Federation
NewVac LLC
Janssen Pharmaceutica N.V., Belgium

Completed

Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

Epithelial Ovarian Cancer | Non-small Cell Lung Cancer

Russian Federation

3

Subscribe